{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:48:54Z","timestamp":1761709734525,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s12185-020-02913-x","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T13:02:27Z","timestamp":1592485347000},"page":"584-591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy"],"prefix":"10.1007","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6220-8657","authenticated-orcid":false,"given":"Yoshinobu","family":"Seki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ouki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Koda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"2913_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. IRIS Investigators. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med."},{"key":"2913_CR2","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2913_CR3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqu\u00e9 C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u2013400.","journal-title":"J Clin Oncol"},{"key":"2913_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1182\/blood-2015-01-617993","volume":"126","author":"S Sau\u00dfele","year":"2015","unstructured":"Sau\u00dfele S, Krau\u00df M, Hehlmann R, Lauseker M, Proetel U, Kalmanti L. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. Blood. 2015;126:42\u20139.","journal-title":"Blood"},{"key":"2913_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"35","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Chrbonnier A, et al. Long-term follow-up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298\u2013305.","journal-title":"J Clin Oncol"},{"key":"2913_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.beha.2016.10.014","volume":"29","author":"FX Mahon","year":"2016","unstructured":"Mahon FX. Discontinuation of TKI therapy and \u2018functional\u2019 cure for CML. Best Pract Res Clin Haematol. 2016;29:308\u201313.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2913_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"108","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;108:185\u201393.","journal-title":"Int J Hematol"},{"key":"2913_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","volume":"109","author":"M Kizaki","year":"2019","unstructured":"Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, et al. Efficacy and safety of tyrosin kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the TARGET system. Int J Hematol. 2019;109:426\u201339.","journal-title":"Int J Hematol"},{"key":"2913_CR9","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.3109\/10428194.2012.695779","volume":"53","author":"JL Steegmann","year":"2012","unstructured":"Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. Leuk Lymphoma. 2012;53:2351\u201361.","journal-title":"Leuk Lymphoma"},{"key":"2913_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/17474086.2015.1041910","volume":"8","author":"BA Carneiro","year":"2015","unstructured":"Carneiro BA, Kaplan JB, Giles FJ. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events. Expert Rev Hematol. 2015;8:457\u201379.","journal-title":"Expert Rev Hematol"},{"key":"2913_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent P, Hadzijusufovic E, Hoermann G, F\u00fcreder W, Schernthaner GH, Sperr WR, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47\u201354.","journal-title":"Leuk Res"},{"key":"2913_CR12","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","volume":"31","author":"E Hadzijusufovic","year":"2017","unstructured":"Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, et al. Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site. Leukemia. 2017;31:2388\u201397.","journal-title":"Leukemia"},{"key":"2913_CR13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.leukres.2017.05.005","volume":"58","author":"M Sukegawa","year":"2017","unstructured":"Sukegawa M, Wang X, Nishioka C, Pan B, Xu K, Ohkawara H, et al. The BCR\/ABL tyrosine kinase inhibitor, nilotinib, stimulates expression of IL-1\u03b2 in vascular endothelium in association with downregulation of miR-3p. Leuk Res. 2017;58:83\u201390.","journal-title":"Leuk Res"},{"key":"2913_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.thromres.2016.07.019","volume":"145","author":"N Alhawiti","year":"2016","unstructured":"Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M, et al. The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state. Thromb Res. 2016;145:54\u201364.","journal-title":"Thromb Res"},{"key":"2913_CR15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","volume":"2","author":"J Douxfils","year":"2016","unstructured":"Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogn\u00e9 JM. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625\u201332.","journal-title":"JAMA Oncol"},{"key":"2913_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/BF01614771","volume":"423","author":"W Min","year":"1993","unstructured":"Min W, Yamanaka N. Three-dimensional analysis of increased vasculature around the glomerular vascular pole in diabetic nephropathy. Virchows Arch A Pathol Anat Histopathol. 1993;423:201\u20137.","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"2913_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2010.3516","author":"S Gupta","year":"2011","unstructured":"Gupta S, Bhatt V, Varma S. Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukemia patient successfully managed with prednisone. BMJ Case Rep. 2011. https:\/\/doi.org\/10.1136\/bcr.11.2010.3516.","journal-title":"BMJ Case Rep"},{"key":"2913_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12185-013-1474-x","volume":"99","author":"L Harbaum","year":"2014","unstructured":"Harbaum L, Marx A, Goekkurt E, Schafhausen P, Atanackovic D. Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity. Int J Hematol. 2014;99:91\u20134.","journal-title":"Int J Hematol"},{"key":"2913_CR19","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015;33:4210\u20138.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-020-02913-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-020-02913-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T23:07:22Z","timestamp":1623971242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-020-02913-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["2913"],"URL":"https:\/\/doi.org\/10.1007\/s12185-020-02913-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"24 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}